Gamma Medica will debut at RSNA 2013 upgrades to its LumaGEM molecular breast imaging system, the company announced.
The system will have a redesigned collimator increasing sensitivity by 20 percent, which will accelerate image acquisition and decrease procedural time, the company said. The company will also introduce an improved breast compression system designed to improve patient stability.
Gamma Medica’s LumaGEM detects tumors as small as 5 mm in mammographically dense and other difficult-to-image breast tissue. The technology can visualize tumors surrounded by non-cancerous glandular tissue, the company said, and may be better than mammography for imaging women with difficult-to-detect lobular tumors, scar tissue from previous surgeries, implants and small distant metastases.